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Summary The prognostic value of immunoperoxidase staining for proliferating cell nuclear antigen
(PCNA) was studied in a series of 140 non-Hodgkin's lymphomas with median follow-up of 9 years.
Lymphomas where >50% of cells showed positive staining for PCNA had inferior 5-year survival as
compared with those with less than 50% of positive cells (57% vs 41%, P = 0.008). The presence of > 50% of
positively staining cells for PCNA was strongly associated with a larger than the median size of the SPF
(median, 8.3%), and high histological grade of malignancy (P<0.0001 for both). Lymphomas with both a
large percentage (> 50%) of PCNA positive cells and a larger than the median SPF had inferior outcome as
compared with lymphomas where either one or both of these factors were small. Although PCNA staining was
not an independent prognostic factor in a multivariate analysis, it appears to be supplementary to the SPF
even if determined from old paraffin-embedded tissue material.
Treatment of non-Hodgkin's lymphoma is currently based
mainly on its histological grade of malignancy, clinical stage
and the performance status of the patient. The biological
behaviour of lymphoma may also be assessed by determining
the rapidity of cell proliferation using various methods, such
as measuring the size of the S phase fraction (SPF) by flow
cytometry (Christensson et al., 1986, and 1989, Young et al.,
1987; Lenner et al., 1987; Cowan et al., 1989; Lehtinen et al.,
1989), assessing expression of Ki-67 antigen (Gerdes et al.,
1984; Grogan et al., 1988; Hall et al., 1988; Brown et al.,
1989), or by immunocytochemical detection of 5-
bromodeoxyuridine (BrdUrd) incorporation in the DNA
(Witzig et al., 1989).
Proliferating cell nuclear antigen (PCNA), also known as
cyclin, is a 36 kD nuclear protein (Bravo & Celis, 1980;
Bravo et al., 1987) that was originally detected by using
autoantibodies from sera of patients with SLE (Miyachi et
al., 1978). PCNA is expressed in a high concentration during
the S phase fraction of the cell cycle in the nuclei of pro-
liferating cells, and in a lesser amount during the GI and
G2/mitosis phases (Kamel et al., 1991). Several commercially
produced antibodies to PCNA are now available, and they
may also work on sections prepared from formalin fixed and
paraffin-embedded tissue (Hall et al., 1990). In the present
paper we have studied the prognostic value of PCNA stain-
ing in an archival series consisting of 140 patients with
non-Hodgkin's lymphoma.
Materials and methods
Patients
The series consists of 140 patients with non-Hodgkin's lym-
phoma (NHL) selected at random from the patients treated
in the Department of Oncology and Radiotherapy, Turku
University Central Hospital, in 1970 to 1984. Seventy-two
(51%) of the patients were male and the median age at the
time of the diagnosis was 63 years (mean, 59 years, range,
from 16 to 86 years). Thirty-eight (27%) patients had B
symptoms (unexplained weight loss of more than 10% of the
usual body weight in the 6 months prior to first attendance,
unexplained fever above 38'C, or night sweats). Staging was
done according the Ann Arbor classification system, and 43
patients had stage I, 30 stage II, 31 stage III and 36 stage IV
disease at presentation.
The patients were followed-up for the median of 104
months (9 years) after the diagnosis (range, from 9 to 213
months) or until death, 96% were followed up at least for 5
years or until death. Sixty-three patients were considered to
have died from lymphoma during the follow-up based on
clinical evidence or an autopsy, 20 from an well-established
intercurrent disease, and in two cases the cause of death
could not be assessed with certainty from hospital and/or
autopsy records. The crude 5-year survival rate was 45%,
and that corrected for intercurrent deaths and deaths from
an unestablished cause 54%.
Treatment was variable, but in localised cases it usually
consisted of involved field or extended field radiotherapy
possibly combined with combination chemotherapy, and in
stages III and IV of combination chemotherapy with or
without irradiation. In 95 cases the primary treatment involv-
ed irradiation (involved field, the mantle field, the inverted
Y-field, or the total nodal irradiation in 54, 25, 11, and five
cases, respectively). Eighty-four patients were treated with
chemotherapy (eight with single agent chlorambucil, 53 with
a combination of three drugs, and 23 with a combination of
four or more drugs). The most often used combinations were
cyclophosphamide, vincristine and prednison (COP, n = 50),
or the same drugs combined with doxorubicin (CHOP,
n= 16).
Histology
The original slides were reviewed and new five micron slides
were sectioned from paraffin blocks, and stained with
hematoxylin and eosin and van Gieson methods. In 18% of
the cases immunoperoxidase staining with antibodies to
immunoglobulin light chains kappa and lambda (Clonab
Biotest, Dreieich D-6072, Germany), leucocyte common
antigen and epithelial membrane antigen (DAKO, Copen-
hagen, Denmark) were used. Forty-one (29%) lymphomas
were graded according to the Working Formulation (WF)
(Rosenberg et al., 1982) scheme as low grade malignant, 53
(38%) as intermediate and 44 (31%) as high grade malig-
nant, and two cases were regarded as unclassifiable. His-
tological distribution of the lymphomas in subgroups is
shown in Table II.
Immunohistochemical staining and scoring ofPCNA
The lymphoma samples had been fixed with 10% neutral
buffered formalin and embedded in paraffin according to
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routine laboratory procedures, and stored in paper boxes in
dark at room temperature (RT). Four micron sections were
cut, mounted on polylysin coated glass slides, deparaffinised
in xylene and rehydrated through a sequence of decreasing
ethanol concentrations, and washed in tris-buffered saline
(TBS). The primary antibody, NCL-PCNA clone PCIO
(Novocastra Laboratories, Newcastle upon Tyne, Great Brit-
ain) in 1% bovine serum albumin (BSA-TBS) was tested at
various concentrations, and the dilution of 1: 50 was chosen
for the study. Nonspecific binding of the primary antibody
was blocked by normal serum. A negative control section
was prepared without the PC1O antibody for each tissue
section. After 1 h incubation at RT the slides were washed in
TBS and treated with ABC complexes (Vectastain, ABC kit
mouse IgG PK-4002, Vector Laboratories, Burlingame, CA
94010, USA) and stained with 3,3'-diaminobenzidine tetra-
hydrochloride (DAB, Polysciences, Inc., Warrington, USA).
After washing with TBS, a slight counterstain with Mayer's
hematoxylin was carried out to visualise the nuclei not
stained with DAB. The staining was successful in all but two
cases.
The part of the section that showed most staining was first
sought using a low magnification. Using a high power
magnification PCNA expression was scored visually in two
ways. First, the percentage of positively staining lymphoma
cells was assessed. Secondly, the intensity of staining was
graded from 0 (no staining), one (weak staining), two
(intermediate staining) to four (strong staining). Using a
consultation microscope (40 x, Leitz Dialux 22, Germany)
two pathologists first examined the slides simultaneously, and
found a consensus regarding both the percentage of
positively staining lymphoma cells, and the intensity of
nuclear staining. The histologic samples of the NHLs were
provided with a numerical code, and PCNA staining score
was done without any knowledge on survival or other
data.
Figure 1 An example of PCNA staining in lymphoblastic lym-
phoma. The stained dark nuclei indicate positive PCNA staining
with the staining intensity ranging from I to 3. The percentage of
positively staining nuclei was considered to be 30%. Only light
background staining is seen. Original magnification x 250.
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Figure 2 Survival corrected for intercurrent deaths by the
percentage of lymphoma cells staining positively for PCNA.
PCNA < 50% positive, n = 61; PCNA >50% positive.
Flow cytometry and Sphasefraction
Flow cytometry was done with a FACSscan Flow Cytometer
(Becton-Dickinson Immunocytometry Systems, Mountain
View, CA) from deparaffinised tissue as described in more
detail elsewhere (Joensuu et al., 1991). DNA was stained with
propidium iodide. The SPF was calculated with the rectan-
gular method without any correction for the background
debris (Camplejohn et al., 1989), and in cases with a large
DNA index (> 1.4) it was calculated for the aneuploid stem-
line only. The SPF could not be calculated in seven cases
because of the small size of the aneuploid peak (<5,000
particles), overlapping stemlines, or the presence of excessive
nuclear debris. The SPF values were also assessed without
any knowledge on clinical data.
Statistical analysis
Statistical analysis was done using a BMDP computer pro-
gram (BMDP Statistical Software, Department of Biomathe-
matics, University of California Press, Los Angeles, CA).
Survival was estimated with the product-limit method, and
comparison of survival between groups was done using the
log-rank test (BMDP IL). Survival rate corrected for known
intercurrent deaths was used in statistical calculations. The
relative importance of prognostic factors was analysed using
Cox's proportional hazard model (BMDP 2L). Frequency
tables were analysed with the chi-squared test. The Spearman
rank correlation coefficient was calculated between the
PCNA percentage and the SPF. All P-values are 2-tailed.
Results
Twelve of the 140 lymphomas were entirely negative in
PCNA staining. In the rest of the cases (n = 128) from 10 to
100% of the lymphoma cell nuclei stained positively for
PCNA (mean, 62%, S.E. 2.5%, median 70%). The staining
intensity of the nuclei was scored as negative (grade 0) in 12
cases, weakly positive (grade 1) in 24 cases, clearly positive
(grade 2) in 59 cases, and strongly positive (grade 3) in 45
cases (Figure 1). There was only little background or cyto-
plasmic staining present.
Staining intensity for PCNA correlated with mortality in
lymphoma. A small subgroup (n = 12) of patients with lym-
phoma with no staining had 91% 5-year and 81% 10-year
survival rates corrected for intercurrent deaths, respectively,
whereas lymphomas that had weak to strong staining inten-
sity (n = 128) were associated with only 51% 5-year and 50%
10-year survival rates, respectively (P = 0.03). There was,PCNA IN MALIGNANT LYMPHOMA 741
however, no difference in survival between the staining inten-
sity sceres 1, 2 and 3.
The percentage of cells with positive staining for PCNA
showed stronger association with survival than staining
intensity. The best cut-off value for the percentage of
positively stained cells was 50%, although a 30% cut-off
value also produced almost as small a P-value as 50% when
tested by the log-rank analysis (P =0.008 vs 0.009, Figure 2).
We examined also the prognostic value of the product of the
staining intensity score (from 0 to 3) multiplied by the
percentage of positively staining cells (from 0 to 100%), but
this combined variable (range, from 0 to 300; mean, 130.4;
S.E. 7.7) failed to show more prognostic value than the
percentage of positively staining cells alone (P = 0.02).
The presence of >50% of positively staining cells for
PCNA was strongly associated with a larger than the median
size of the SPF (median, 8.3%), and high histological grade
of malignancy (P<0.0001 for both, Table I). Seventy-three
percent of low grade malignant lymphomas had less than
50% of lymphoma cells staining positively for PCNA,
whereas 80% of lymphomas with high grade of malignancy
had > 50% positively staining cells. The association between
Working Formulation classification and PCNA staining is
shown in Table II. The size of the SPF became larger as the
percentage of positively staining cells increased (r = 0.51,
P<0.001, Table III). Twenty (39%) of the DNA aneuploid
Table I Association between PCNA staining, S phase fraction
(SPF) and Working Formulation (WF) grading
Percentage of lymphoma cells
with positive staining
for PCNA
<50% >50%
Factor N (%) N (%) P
Size of SPFI
<8.3% 42 (72) 26 (35)
>8.3% 16 (28) 49 (65) P <0.0001
WF gradeb
Low 30 (73) 11 (27)
Intermediate 22 (42) 31 (58)
High 9 (21) 35 (80) P <0.0001
aSPF was not calculated in seven cases. bTwo cases were
considered as unclassifiable.
Table II Association of PCNA staining and Working Formulation
classification
PCNA staining
<50% positive >50% positive
Working formulation n N (%) N (%)
Low grade
A. Small cell, 18 16 (89) 2 (11)
lymphocytic
B. Small cleaved, 12 9 (75) 3 (25)
follicular
C. Mixed cell, 11 5 (45) 6 (55)
follicular
Intermediate grade
D. Predom. large, 2 0 2 (100)
follicular
E. Small cleaved, 16 11 (69) 5 (31)
diffuse
F. Mixed cell, diffuse 24 8 (33) 16 (67)
G. Large cell, diffuse 11 3 (27) 8 (73)
High grade
H. Large cell, 19 3 (16) 16 (84)
immunoblastic
I. Lymphoblastic 24 6 (25) 18 (75)
J. Small, non-cleaved 1 0 1 (100)
cell
Miscellaneous 2 0 2 (100)
Total 140 61 (44) 79 (56)
Table III Association between PCNA staining and the size of the S
phase fraction in 133 non-Hodgkin's lymphoma
Percentage of S phase fraction
PCNA positive Mean (S.E.) Range Median
cells N % % %
0-20 26 5.9 (0.8) 1.4-19.0 5.0
21-40 25 6.5 (0.7) 2.3-13.2 5.7
41-60 17 9.3 (1.5) 3.2-25.6 6.8
61-80 34 11.0 (1.4) 2.5-38.4 8.8
81-100 31 16.3 (1.7) 3.4-41.0 13.3
Total 133 10.2 (0.8) 1.4-41.0 8.3
lymphomas had <50% nuclei that stained positively for
PCNA as compared with 41 (46%) of DNA diploid lym-
phomas (P = 0.43).
Lymphomas with an SPF larger than the median were
associated with unfavourable prognosis (Figure 3). If the SPF
was smaller than 8.3%, and less than 50% oflymphoma cells
stained positively for PCNA, 63% of such patients were alive
5 years after the diagnosis, whereas if the SPF was >8.3%
and >50% of lymphoma cells gave a positive staining for
for PCNA, only 41% of the patients were alive at 5 years
from the diagnosis. If only one of these two factors was
large, the 5-year survival rate was poorer than in cases where
the SPF was <8.3% and <50% of cells stained positively
for PCNA, but better than in cases where the SPF was
>8.3% and >50% cells were positive for PCNA (Figure
4).
In clinical stages I and II lymphomas with <50%
positively staining nuclei for PCNA (n= 34) had 84% 5- and
10-year survival rates as compared with 54% and 51%
among lymphomas with >50% positive nuclei, respectively
(n = 39, P = 0.002). The size of the SPF also correlated well
with the final outcome in stages I and II. If the SPF was
<8.3% (n = 35) the 5- and 10-year survival rates were 78
and 75%, respectively, and if it was greater than 8.3%
(n= 33), both 5- and 10-year survival rates were 54%
(P 0.006).
Several factors were associated with survival when they
were tested as a single variable (Table IV). They included
Ann Arbor clinical stage (P<0.0001), Working Formulation
grading (P = 0.002), and sex (P =0.01) in addition to the size
of the SPF and PCNA staining, but age at the time of the
diagnosis, the presence of B symptoms and DNA ploidy did
not correlate significantly with survival. When PCNA stain-
ing (the percentage of positive nuclei) and the SPF were
entered into Cox's multivariate analysis as continuous vari-
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Figure 3 Survival corrected for intercurrent deaths by the size of
the S phase faction (median, 8.3%). SPF < 8.3%, n = 68;
SPF>8.3%, n = 65.742 P.J. KLEMI et al.
ables together the four other significant prognostic factors
found in univariate analyses (Ann Arbor stage, Working
Formulation grading, PCNA staining intensity, and sex),
stage (P = 0.001) and Working Formulation grading (P =
0.001) turned out to have independent prognostic influence,
whereas the SPF, PCNA staining, and sex did not (Table
V).
A: PCNA<50% AND SPF<8.3%
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Figure 4 Survival corrected for intercurrent deaths by the com-
bination of PCNA staining and the size of the S phase fraction.
Curve A, n = 42; curve B, n = 16, curve C, n = 26; curve D,
n = 49.
Discussion
A good correlation between the percentage of lymphoma
cells that stined positively for PCNA and the size of the S
phase fraction was found in the present series consisting of
patients with non-Hodgkin's lymphoma. A similar result has
been obtained earlier in primary gastrointestinal lymphomas
(Woods et al., 1991), and low PCNA grading had also been
found to be a favourable prognostic factor in other human
neoplasms, such as gastric carcinoma (Jain et al., 1991) and
haemangiopericytomas (Yu et al., 1991). Our finding is in
line with earlier reports, where a good correlation between
PCNA staining and staining for the Ki-67 antibody in non-
Hodgkin's lymphoma (Hall et al., 1990, Kamel et al., 1991),
and between PCNA staining and bromodeoxiuridine incor-
poration in MCF-7 human breast cancer cell line were dem-
onstrated (van Dierendonck et al., 1991). The percentage of
cells staining positively for PCNA also correlated with mor-
tality in lymphoma in a univariate analysis, and it appeared
to supplement the SPF in predicting the final outcome
(Figure 4). Furthermore, a good correlation between his-
tological grading by the Working Formulation scheme and
PCNA staining could be demonstrated (Tables I and II).
Hence, it appears that PCNA may be used as a marker of
cell proliferation in clinical studies to estimate the biological
aggressiveness of lymphoma.
There are, however, methodological aspects that need to be
considered. The assessment of PCNA staining is probably
more subjective and less easy to standardise than calculation
of the S phase fraction from the histograms obtained by flow
cytometry. However, the percentage of postively staining
lymphoma cells is relatively easy and quick to estimate, and
Table IV Influence of nine factors on survival among 140 patients with non-Hodgkin's
lymphoma
Corrected survival
5-yr 10-yr Chi
Factor N (%) (%) (%) squared P
Clinical stage
I 43 (31) 83 80 27.9 <0.0001
II 30 (21) 44 44
III 31 (22) 57 49
IV 36 (26) 27 27
Working Formulation grade
Low 41 (29) 73 70 12.3 0.002
Intermediate 53 (38) 53 50
High 44 (31) 39 39
Unclassified 2 (1)
SPFa
<,8.3% 68 (51) 63 59 8.5 0.004
>8.3% 65 (49) 44 44
PCNA nuclear staining
percentage
<50% 61 (44) 63 61 7.1 0.008
> 50% 79 (56) 47 46
Sex
Male 72 (51) 44 42 6.0 0.01
Female 68 (49) 65 63
PCNA nuclear staining
intensity score
0 12 (9) 91 81 4.5 0.03
1-3 128 (91) 51 50
Agea
<63 yr 72 (51) 60 58 3.2 0.07
>63 yr 68 (49) 48 45
DNA ploidy
Diploid 89 (64) 55 53 0.8 0.36
Nondiploid 51 (36) 51 51
B-symptoms
No 101 (73) 58 55 0.6 0.44
Present 38 (27) 46 46
aThe median was used as the cut-off value.PCNA IN MALIGNANT LYMPHOMA 743
Table V Results of Cox's Stepwise Proportional Hazard Model
Relative risk Step of
Factor P S.E. (a) p/S.E.a P of death (en) removal
Ann Arbor stage 0.52 0.11 4.72 <0.001 1.7 (1.3-2.1)b 1.
WF grading 0.56 0.17 3.29 <0.001 1.8 (1.3-2.4) 2.
SPF N.S.C
Percentage of positive N.S.C
cells in PCNA staining
PCNA staining intensity N.S.C
Sex N.S.C
apis the estimated regression coefficient of the hazard function, S.E. is the standard error, and P/S.E.
(z value) describes their significance. "The 95% confidence limits are given for the relative risk of death.
CN.S. = not significant.
it appears to be a better discriminator of survival than
staining intensity. Quantitation of PCNA staining may also
become more objective by the use of image analysers.
Different antibodies to PCNA are available, and it is not
certain if they all will show similar association to survival,
and other factors, such as the dilution of the antibody may
be of importance. We found the dilution 1:50 to work best
in our material, which may not be true for other series and
for other antibodies (Kamel et al., 1991). Hence, each
laboratory may have to find their own method to assess
PCNA staining, and to find their optimal dilution.
We used formalin-fixed and paraffin-embedded tissue,
which is easily available and makes it possible to assess the
association between long-term outcome and PCNA staining.
However, fixation may affect staining for PCNA (van
Dierendonck et al., 1991), and it is not known whether a
stronger association between survival and PCNA staining
would have been obtained if fresh material had been used.
Yet, the results of the present study carried out in a blinded
fashion are encouraging, and PCNA staining appears to be
of value even if performed from fixed starting material.
Moreover, the correlation between the percentage of PCNA
stained nuclei and mortality caused by lymphoma may fur-
ther improve when large series with uniform treatment are
investigated.
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